Fig. 1.

A Potential precision medicine model for steroid sensitive nephrotic syndrome. Current phenotyping of steroid sensitive nephrotic syndrome is limited to clinical features. In the future, deep phenotyping may be available based on genetic variants and biomolecular profiles. Biomarkers can be incorporated into clinical trials to identify children who will benefit most from existing and new therapies, ultimately leading to a precision medicine approach where treatment is personalized to achieve the optimal outcome for each individual child. B Graphical example of an adaptive platform trial with integration of biomarkers. Pre-specified changes can be made during planned interim analyses of trial data. Treatment arms may be dropped due to futility, a superior treatment can replace the standard of care, and new treatment arms can be introduced as novel agents become available and biomarker enrichment strategies can be used